Absci

Absci’s moat today is primarily intangible assets: proprietary datasets, the Origin-1 generative design model, reverse immunology target discovery know-how, and a growing IP base. Origin-1’s claimed ability to design full-length antibodies against zero-prior epitopes with cryo-EM confirmation is differentiated, though still early in external proof.

We do not see classic network effects, and switching costs for pharma partners remain modest given the project-based nature of engagements. Cost advantage may emerge if the lab-in-the-loop reduces screens and accelerates time to clinic, but this advantage is unproven at scale.

Efficient scale is limited by the capital intensity of wet lab plus compute. Component scores: intangible assets 60/100, switching costs 30/100, network effects 10/100, cost advantage 35/100, efficient scale 25/100; weighted moat score approximately 42/100. Key supports: Origin-1 description and validations disclosed in the 2025 10-K.